Fulltext

A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design

Nakamoto H 1 , Fujita T , Origasa H , Isono M , Kurumatani H , Okada K Show all authors , Kanoh H , Kiriyama T , Yamada S

Affiliations 

  • 1 Department of General Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyamamachi, Iruma-gun, Saitama 350-0495, Japan. nakamo_h@saitama-med.ac.jp
BMC Nephrol, 2014;15:153.
PMID: 25233856 DOI: 10.1186/1471-2369-15-153

Abstract

Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration function, containing in slope of 1/serum creatinine (1/SCr) vs. time in a phase II clinical trial.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications